secwatch / observer
8-K filed May 27, 2026, 4:21 PM ET ticker IMCR CIK 0001671927
other confidence high sentiment neutral materiality 0.15

Immunocore shareholders approve all 10 resolutions at 2026 AGM

Immunocore Holdings plc

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunocore Holdings plc shareholders approved Re-appointment of Deloitte LLP as U.K. statutory auditors at the 2026-05-27 meeting.

Outcome
passed
Meeting
2026-05-27
Exact text from the filing
Resolution 6 : To re-appoint Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. The votes were cast as follows: For Against Abstain 38,294,523 966 8,351
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunocore Holdings plc shareholders approved Re-appointment of William Pao as director at the 2026-05-27 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-05-27
Exact text from the filing
Resolution 2 : To re-appoint as a director of the Company William Pao, M.D., Ph.D. The votes were cast as follows: For Against Abstain 38,040,755 254,852 8,233
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunocore Holdings plc shareholders approved Authorization to make political donations/incur political expenditure at the 2026-05-27 meeting.

Outcome
passed
Meeting
2026-05-27
Exact text from the filing
Resolution 10 : To authorize the Company to make political donations/incur political expenditure. The votes were cast as follows: For Against Abstain 38,213,340 82,113 8,387
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunocore Holdings plc shareholders approved Receive and adopt U.K. statutory annual accounts and reports for 2025 at the 2026-05-27 meeting.

Outcome
passed
Meeting
2026-05-27
Exact text from the filing
Resolution 8 : To receive and adopt the U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). The votes were cast as follows: For Against Abstain 38,287,987 944 14,909
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunocore Holdings plc shareholders approved Re-appointment of Siddharth Kaul as director at the 2026-05-27 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-05-27
Exact text from the filing
Resolution 1 : To re-appoint as a director of the Company Siddharth Kaul. The votes were cast as follows: For Against Abstain 38,033,664 261,819 8,357
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunocore Holdings plc shareholders approved Authorization to audit committee to determine U.K. statutory auditors’ remuneration for 2026 at the 2026-05-27 meeting.

Outcome
passed
Meeting
2026-05-27
Exact text from the filing
Resolution 7 : To authorize the audit committee to determine the U.K. statutory auditors’ remuneration for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 38,293,269 2,481 8,090
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunocore Holdings plc shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-27 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-05-27
Exact text from the filing
Resolution 4: To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: For Against Abstain 29,682,169 8,600,029 21,642
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunocore Holdings plc shareholders approved Ratification of Deloitte LLP as U.S. independent registered public accounting firm for 2026 at the 2026-05-27 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-05-27
Exact text from the filing
Resolution 5: To ratify the appointment of Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 38,294,666 984 8,190
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunocore Holdings plc shareholders approved Re-appointment of Kristine Peterson as director at the 2026-05-27 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-05-27
Exact text from the filing
Resolution 3 : To re-appoint as a director of the Company Kristine Peterson. The votes were cast as follows: For Against Abstain 29,537,800 8,744,383 21,657
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunocore Holdings plc shareholders approved Approval of directors' remuneration report for 2025 (excluding policy) at the 2026-05-27 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-05-27
Exact text from the filing
Resolution 9 : To approve the directors’ remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 26 to 56 of the 2025 U.K. Annual Report (excluding the directors’ remuneration policy set out on pages A-5 to A-15 of Annex A to the Proxy Statement). The votes were cast as follows: For Against Abstain 29,504,692 8,713,573 85,575
View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Immunocore Holdings plc filing history →

Source: SEC EDGAR
accession 0001140361-26-022984
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.